{"id":17468,"date":"2021-09-23T10:57:44","date_gmt":"2021-09-23T17:57:44","guid":{"rendered":"https:\/\/marketdepth.com\/?p=17468"},"modified":"2021-09-29T08:45:39","modified_gmt":"2021-09-29T15:45:39","slug":"transcode-therapeutics-surges-on-new-cancer-nanotechnology-publication","status":"publish","type":"post","link":"https:\/\/marketdepth.com\/transcode-therapeutics-surges-on-new-cancer-nanotechnology-publication\/","title":{"rendered":"TransCode Therapeutics Surges on New Cancer Nanotechnology Publication"},"content":{"rendered":"\n
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.<\/em> \u201cThe imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode\u2019s TTX platform for delivery of RNA targeted therapy to metastatic solid tumors,\u201d according <\/a>to the company\u2019s press release.<\/p>\n\n\n\n TransCode Therapeutics stock gained over 26% in premarket trading.\u00a0<\/p>\n\n\n\n The key results of the study showed that TTX-MC138 accumulated in metastatic lesions once after being injected intravenously, with the results of the study suggesting that the platform delivers its therapeutic candidate as intended.\u00a0<\/p>\n\n\n\n \u201cOur TTX technology builds upon prior experience with similar iron oxide nanoparticles that have long been used in humans for imaging, potentially enabling clinical studies that may de-risk future clinical trials by demonstrating successful drug delivery and assist in patient selection for future treatment.”\u00a0<\/p>Michael Dudley, CEO of TransCode Therapeutics<\/cite><\/blockquote>\n","protected":false},"excerpt":{"rendered":"TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology. \u201cThe imaging study confirms the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode\u2019s TTX platform for delivery of RNA targeted therapy to metastatic solid tumors,\u201d according to the company\u2019s press release. Up 26%… View Article<\/a>","protected":false},"author":3,"featured_media":17469,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":0,"footnotes":""},"categories":[9,17,8,11,16],"tags":[],"acf":[],"yoast_head":"\nUp 26% Premarket<\/h5>\n\n\n\n
Results as Intended<\/h5>\n\n\n\n